Skip to main content
. 2019 Oct 14;10(6):1408–1410. doi: 10.1111/jdi.13150

Table 1.

Major benefits and risks of sodium–glucose cotransporter 2 inhibitors use

Benefits Risks

  • Plasma glucose ↓

  • Bodyweight ↓

  • Body fat ↓

  • Blood pressure ↓

  • MACE ↓

  • HF hospitalization ↓

  • Renal protection

  • GTI

  • UTI

  • DKA (especially used in type 1 diabetes)

  • Hypoglycemia (with insulin or SU)

  • Volume depletion

  • Skin lesion

DKA, diabetic ketoacidosis; GTI, genital tract infection; HF, heart failure; MACE, major adverse cardiovascular events; SGLT2, sodium–glucose cotransporter 2; SU, Sulfonylureas; UTI, urinary tract infection.